Pfizer Inc v Commissioner of Patents

Link copied
Case Copied 58 min read

IN THE COURT OF APPEAL OF NEW ZEALAND

CA22/03

BETWEENPFIZER INC


Appellant

ANDCOMMISSIONER OF PATENTS


Respondent

Hearing:9 and 10 February 2004

Coram:Anderson P
Glazebrook J
Hammond J
William Young J
O'Regan J

Appearances:  A H Brown QC and G F Arthur for Appellant


B W F Brown QC and D A Laurenson for Respondent

Judgment:28 June 2004 

JUDGMENTS OF THE COURT

Judgments

PARA NO

ANDERSON P  [1]-[8]

Glazebrook, William Young and O’Regan JJ                  [9]-[94]
Hammond J  [95]-[134]

ANDERSON P

[1]       This Court held in Wellcome Foundation Ltd v Commissioner of Patents [1983] NZLR 385 that a patent may not be granted under the Patents Act 1953 for a method of treating disease or illness in human beings. That view was conventional. It conformed with English jurisprudence which had its roots in the Statute of Monopolies 1623 (21Jac 1,c3), s6 of which is imported by reference into the New Zealand statute.

[2]       The Jacobean statute may have been more aptly named the Statute against Monopolies, for its elemental purpose was to proscribe the royal grant of monopolies; but consistent with an appreciation that it is in the public interest to encourage inventiveness and the dissemination of knowledge the statute accepted “any manner of new manufactures” provided “they be not contrary to the law, nor mischievous to the State, by raising prices of commodities at home, or hurt of trade, or generally inconvenient”.  A monopoly could be granted by letters patent and grants of privilege for a term of up to 14 years “to the true and first inventor and inventors of such manufactures”.

[3]       Over the past four centuries public interest has led the Courts to expand the concept of “manner of new manufactures” to connote almost any new discovery outside the ambit of the s6 proviso.  The meaning of s6, and therefore the patentability of a discovery, is a matter of evolved judicial interpretation.  The juridical basis for the exclusion of methods of medical treatment lies therefore not in a narrow reading of the ancient statute but in the historical and conceptual connotations of its judicial exposition.  As the High Court of Australia explained in National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252 at 269:

The inquiry which the definition demands is an inquiry into the scope of the permissible subject matters of letters patent and grants of privilege … it is an inquiry not into the meaning of a word so much as into the breadth of the concept which the law has developed by its consideration of the text and purpose of the Statute of Monopolies.

[4]       Although methods of medical treatment were considered incapable of being patented, the use of a known compound for a recognised inventive purpose evolved into what is known as a Swiss claim.  The purpose of such claims is to accord, for socially utile reasons, a monopoly which permits the economic exploitation of an intellectual discovery without constraining its potential for use once paid for.  The device rewards…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pfizer Inc v Commissioner of Patents and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] NZCA 104
Decision Date

CaseChat Overview and Summary

This appeal concerns the patentability of methods of medical treatment under the Patents Act 1953. Pfizer Inc (Pfizer) sought to patent two methods of treating psychotic disorders using a new compound. The Assistant Commissioner of Patents declined to accept Pfizer’s patent applications on the basis that methods of medical treatment of humans were excluded from patentability. Pfizer appealed to the High Court, which dismissed its appeal, and Pfizer now appeals to this Court. The Court dismissed Pfizer’s appeal. This Court has long held that methods of medical treatment of humans are not patentable in New Zealand. This Court’s decision in Pharmac Pharmaceutical Management Agency Ltd v Commissioner of Patents [2000] 2 NZLR 529 (Pharmac) concerned the patentability of Swiss claims, which are used to circumvent prohibitions on patenting methods of medical treatment. The Court in Pharmac held that Swiss claims were inventions and could be patented. Pfizer submitted that Pharmac overrules Wellcome Foundation Ltd v Commissioner of Patents [1983] NZLR 385 (Wellcome) and that the Court should now overrule Wellcome and permit the patenting of methods of medical treatment. The Court held that Pharmac did not overrule Wellcome. Nor did subsequent developments provide a basis for the Court to overrule Wellcome. The Court also rejected Pfizer’s proposal to permit the patenting of methods of medical treatment subject to a disclaimer not to sue medical practitioners. The Court held that Parliament should determine whether methods of medical treatment should be patentable.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established